What is the Cause of Antiphospholipid Syndrome (APS)?
Antiphospholipid syndrome is caused by pathogenic antiphospholipid antibodies (aPL) that target phospholipid-binding proteins, particularly beta-2-glycoprotein I (β2GPI), triggering a thrombo-inflammatory cascade that leads to thrombosis and pregnancy complications. 1
The Autoimmune Mechanism
APS is fundamentally an autoimmune thrombo-inflammatory disease driven by antiphospholipid antibodies 1. These antibodies recognize and bind to phospholipid surfaces and phospholipid-binding proteins, particularly β2GPI, which serves as the primary autoantigen 2. When aPL bind to these targets, they induce thrombosis, pregnancy morbidity, and various inflammatory manifestations 1.
The pathogenic antibodies are not simply directed at phospholipids themselves. Rather, they target protein cofactors—especially β2GPI—either directly or when these proteins are bound to phospholipids 3. This distinction is critical: cofactor-dependent and cofactor-directed antibodies (types 2 and 3) are pathogenic and cause clinical disease, while cofactor-independent antibodies (type 1) are typically non-pathogenic 3.
Environmental Triggers and Molecular Mimicry
The development of pathogenic aPL involves a combination of genetic susceptibility and environmental factors. Infectious agents are the most significant environmental trigger, followed by trauma and drugs 4.
The mechanism involves molecular mimicry: certain bacterial or viral proteins contain epitopes that resemble molecular domains in β2GPI—specifically regions with strong positive charge and hydrophobicity that facilitate binding to negatively charged phospholipids 2. In genetically susceptible individuals, exposure to these infectious agents breaks immune tolerance to self-β2GPI and phospholipids, resulting in production of pathogenic autoantibodies 2, 4.
Approximately one-third of catastrophic APS cases are clearly associated with recent infection 4. However, post-infectious aPL are rarely associated with thrombosis or pregnancy complications unless they target the specific pathogenic epitopes 2.
Recent Mechanistic Insights: The PF4 Connection
Emerging research from 2026 reveals that platelet factor 4 (PF4) plays a central bridging role in APS pathogenesis 5. PF4 binds to β2GPI and enhances recognition by APS antibodies. Critically, PF4 bridges β2GPI to neutrophil extracellular traps (NETs), forming prothrombotic PF4:β2GPI:NET immunocomplexes that serve as multimolecular antigenic targets 5. This positions APS as a PF4-centric immunothrombotic disorder with mechanistic parallels to other PF4-mediated thrombotic conditions 5.
The Pathogenic Cascade
Once formed, aPL are clearly pathogenic through multiple mechanisms 4:
- They influence all components of the coagulation system
- They activate endothelial cells, promoting a prothrombotic state 6, 3
- They trigger complement system activation 7
- They induce NET formation, creating thrombotic scaffolds 5
- They interact with platelets through PF4-mediated mechanisms 5
The heterogeneity of aPL explains the diverse clinical manifestations of APS 6, 3. Different antibodies have different mechanisms of action, affecting various aspects of hemostasis and inflammation.
Clinical Implications
Understanding that APS is antibody-driven has direct diagnostic implications: diagnosis depends entirely on accurate detection and interpretation of aPL, as clinical features are non-specific 1. The cornerstone laboratory tests remain lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-β2GPI antibodies (aβ2GPI) 1.
Risk stratification correlates with antibody profile: triple-positive patients (positive for LA, aCL, and aβ2GPI) have the highest thrombotic risk, while single-positive LA carries lower risk 1. This antibody-driven risk gradient directly reflects the underlying pathogenic mechanisms.